The Supreme Court Temporarily Restores Access to a Key Abortion Drug
The Supreme Court has taken action to temporarily restore mail and pharmacy access to a widely used abortion drug, mifepristone. This decision came after a conservative federal appeals court recently cut off access, which advocates argue is the biggest threat to abortion care since the landmark ruling in Roe v Wade was overturned.
If the appeals court’s order remains in effect, patients across the country would be required to travel to a health center to pick up the mifepristone pill in person. For many individuals living in states where abortion is banned, this could mean traveling hundreds of miles, creating significant barriers to accessing critical reproductive healthcare.
The Supreme Court’s emergency relief will expire on May 11, setting the stage for another high-profile legal battle over abortion rights at the nation’s highest court. This ongoing uncertainty highlights the instability of reproductive healthcare access in the United States.
Julia Kaye, senior staff attorney for the Reproductive Freedom Project of the ACLU, expressed cautious optimism about the court’s decision. “While this is a positive short-term development, no one can rest easy when our ability to get this safe, effective medication for abortion and miscarriage care still hangs in the balance,” she said in a statement. She emphasized that the Supreme Court needs to put an end to what she calls a baseless attack on reproductive freedom.
Nourbese Flint, president of the abortion rights group All* Above All, described the situation as a “week-to-week rollercoaster” that destabilizes providers and sows fear and confusion among those seeking time-sensitive care. “Abortion access that hinges on back-and-forth legal decisions underscores just how unstable and politicized abortion access has become in this country,” she said.
Since the Supreme Court revoked the constitutional right to abortion care in 2022, more than a dozen states have outlawed abortions in virtually all circumstances. This has created a patchwork of abortion access across the country, with some states adding legal constraints for patients and providers. In some states, abortion is shielded from legal repercussions, while in others, it is criminalized.
Medication abortion now accounts for the vast majority of abortions. According to the Guttmacher Institute, a reproductive health advocacy group, roughly 63 percent of all abortions are now medication abortions. Mifepristone, one of two prescription drugs used in medication abortions, is approved by the Food and Drug Administration (FDA) up to 10 weeks of pregnancy. Nearly 93 percent of all abortions were performed before the 13th week, according to the Centers for Disease Control and Prevention.
The drug is also widely used for miscarriage care and is available through telemedicine, allowing patients to take the drug at home rather than in a clinic under doctor supervision. More than one in four people who have an abortion get their medication through telemedicine, according to Guttmacher.
Anti-abortion activists are pushing for further restrictions, while President Donald Trump’s allies and Republican lawmakers are urging the FDA to revoke mifepristone’s approval altogether. Critics call this a backdoor effort to ban abortion nationally. The Trump administration has pledged to revisit the drug’s approval process, which was first granted over 20 years ago.
In 2021, the FDA under then-President Joe Biden permanently lifted the in-person requirement for mifepristone prescriptions, allowing patients to access the drugs via telehealth appointments and online pharmacies. However, on May 1, the Fifth Circuit Court of Appeals in Louisiana reinstated a nationwide requirement that patients obtain the drug in person, upending abortion access for millions of people across the country.
Drug manufacturers then turned to the Supreme Court to block the ruling. Lawyers for GenBioPro, the manufacturer of mifepristone, wrote in an emergency filing that the order is deeply unsettling to drug sponsors, healthcare providers, patients, and the public. They emphasized the importance of the FDA’s scientific judgment and orderly administration of the drug regulation system.
Kelly Baden, vice president for public policy at the Guttmacher Institute, called the appeals court decision the “most sweeping threat” to abortion access since the Supreme Court overturned Roe v Wade. “Reimposing medically unnecessary in-person dispensing requirements for mifepristone will send shockwaves of chaos and confusion across the country and dramatically upend patients’ ability to obtain abortion care,” she said.
The Supreme Court’s latest move provides “critical short-term relief” for abortion patients, but the underlying threat to access remains dire, she added. Nancy Northup, president of the Center for Reproductive Rights, urged continued vigilance. “This ruling is not final — keep watching.”
Getting abortion pills through telehealth has been a lifeline for women since Roe v Wade was overturned, she said. “There is no reason people shouldn’t be able to get mifepristone at a pharmacy or through the mail. Louisiana’s attempt to restrict access is political and not based in science or medicine.”
According to a survey by the Committee to Protect Health Care, a political advocacy group of 36,000 medical workers, nearly three-quarters of voters believe decisions about medication abortion should be between a woman and her healthcare provider. The survey also found that 60 percent of voters don’t want courts to overrule doctors and the FDA on abortion drugs, and 57 percent said a state’s abortion ban should not be used to restrict access to telehealth prescriptions for abortion drugs.
Roughly one-quarter of respondents said states that ban abortion should also be able to stop doctors in other states from prescribing medication abortion across state lines.
